2012: A Healthy Year for the Life Sciences
We’ll start our recap of The Life Sciences Report’s inaugural year with the comments of Geoff Meacham, senior analyst and managing director at JPMorgan Chase. Hepatitis C In his Jan. 31 interview (Hepatitis . . . → Read More: 2012: A Healthy Year for the Life Sciences Similar posts: Emerging Gold Juniors and Explorers Should Recover in 2012: Jeff Berwick The Gold Report: Your newsletter, The Dollar Vigilante, is the... Biotech Stocks Start Strong in 2012: John McCamant The Life Sciences Report: John, I’m looking at a basket... Infectious Disease Technologies Could Open Investment Opportunities in 2012: Stephen Dunn The Life Sciences Report: Why is there such a disproportionate...
We’ll start our recap of The Life Sciences Report’s inaugural year with the comments of Geoff Meacham, senior analyst and managing director at JPMorgan Chase.
Hepatitis C
In his Jan. 31 interview (Hepatitis C and Orphan Diseases Driving Big Biotech Potential), Meacham said this about the outlook for hepatitis C (HCV) and orphan diseases:
“We’ve been talking about [HCV] for about two years, and it is still going to be a tremendous source of interest and innovation, no doubt about it. I think what’s attracted a lot of people is that you can derisk a … [visit site to read more]
Similar posts:- Emerging Gold Juniors and Explorers Should Recover in 2012: Jeff Berwick The Gold Report: Your newsletter, The Dollar Vigilante, is the...
- Biotech Stocks Start Strong in 2012: John McCamant The Life Sciences Report: John, I’m looking at a basket...
- Infectious Disease Technologies Could Open Investment Opportunities in 2012: Stephen Dunn The Life Sciences Report: Why is there such a disproportionate...